Cost of severe hypoglycaemia in nine European countries

References

• Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855-62
   PubMed Web of Science ®Google Scholar
• Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of Economics, 2012. http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf. Accessed July 2013
   Google Scholar
• Šarić T, Benković V, Poljicanin T, et al. Cost of diabetes in Croatia. Impact of complications on the costs of type II diabetes. ISPOR 14th Annual European Congress Madrid, 2011: PDB31. http://www.ispor.org/congresses/Spain1111/Posters3.aspx. Accessed October 2012
   Google Scholar
• Vokó Z, Nagyjánosi L, Kaló Z. Direct health care costs of diabetes mellitus in Hungary. LAM 2009;19:775-80
   Google Scholar
• Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
   PubMedGoogle Scholar
• Kruntorádová K, Suchánková E, Klimeš J, et al. Costs of hypoglycaemia of diabetic patients: cost-of-illness study. Farmakoekonomika 2012;6:17-21
   Google Scholar
• Saunders R, Lian J, Karolicki B, et al. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. J Med Econ 2014;17:827-36
   PubMedGoogle Scholar
• Brown ST, Grima DG, Sauriol L. Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus. Clin Ther 2014;36:1576-87
   PubMed Web of Science ®Google Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015;18:56-68
   PubMed Web of Science ®Google Scholar
• Kiadaliri AA, Gerdtham UG, Eliasson B, et al. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in Sweden. Diabetes Ther 2014;5:591-607
   PubMed Web of Science ®Google Scholar
• Ly TT, Brnabic AJ, Eggleston A, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014;17:561-9
   PubMed Web of Science ®Google Scholar
• van Dijk CE, Hoekstra T, Verheij RA, et al. Type II diabetes patients in primary care: profiles of healthcare utilization obtained from observational data. BMC Health Serv Res 2013;13:7
   PubMed Web of Science ®Google Scholar
• Frier BM. The economic cost of hypoglycaemia. Br J Diabetes Vasc Dis 2011;11(1 Suppl):S10-S12
   Google Scholar
• Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002;25:2109-10
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80
   PubMed Web of Science ®Google Scholar
• Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
   PubMed Web of Science ®Google Scholar
• van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.
   PubMed Web of Science ®Google Scholar
• Czech M, Rdzanek E, Pawęska J, et al. Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocr Disord 2015;15:57
   PubMed Web of Science ®Google Scholar
• Jakubczyk M, Rdzanek E, Niewada M, et al. Economic resources consumption structure in severe hypoglycemia episodes: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2015;15:813-22
   PubMed Web of Science ®Google Scholar
• Nordfeldt S, Jonsson D. Short-term effects of severe hypoglycaemia in children and adolescents with type 1 diabetes. A cost-of-illness study. Acta Paediatr 2001;90:137-42
   PubMed Web of Science ®Google Scholar
• Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703
   PubMed Web of Science ®Google Scholar
• Allicar MP, Mégas F, Houzard S, et al. Frequency and costs of hospital stays for hypoglycemia in France in 1995. Presse Med 2000;29:657-61
   PubMed Web of Science ®Google Scholar
• Borissova AM, Shinkov A, Vlahov J, et al. Prevalence of diabetes mellitus and prediabetes in Bulgaria Today. J Bulgarian Soc Endocrinol 2012;4. http://endo-bg.com/node/741. Accessed July 2007
   Google Scholar
• IDF Diabetes Atlas Fourth Edition. International Diabetes Federation, 2009. https://www.idf.org/sites/default/files/IDF-Diabetes-Atlas-4th-edition.pdf Accessed October 2014
   Google Scholar
• IDF Diabetes Atlas 5th Edition. International Diabetes Federation, 2011. https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed October 2014
   Google Scholar
• Metelko Z, Pavlić-Renar I, Poljicanin T, et al. Prevalence of diabetes mellitus in Croatia. Diabetes Res Clin Pract 2008;81:263-7
   PubMed Web of Science ®Google Scholar
• Poljicanin T, Pavlić-Renar I, Metelko Z. CroDiab NET-electronic diabetes registry. Acta Med Croatica 2005;59:185-9
   PubMedGoogle Scholar
• HZJZ. Croatian Health Service Yearbook, 2011. Zagreb: Croatian National Institute Of Public Health, 2012
   Google Scholar
• Ústav zdravotnických informací a statistiky ČR (Institute of Health Information and Statistics of the Czech Republic). http://www.uzic.cz. Accessed October 2012
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas. Accessed October 2014
   Google Scholar
• Rombopoulos G, Hatzikou M, Latsou D, et al. The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (The HYPO Study). Hormones (Athens) 2013;12:550-8
   PubMedGoogle Scholar
• Jankowski M, Bała MM, Płaczkiewicz-Jankowska E, et al. Specialty outpatient care of diabetic patients in Poland-are we far from treatment targets? Rationale, design, and preliminary results of the OPTIMO study. Pol Arch Med Wewn 2011;121:375-8
   PubMed Web of Science ®Google Scholar
• Wittek A, Sokalski B, Grzeszczak W, et al. Prevalence of diabetes and cardiovascular risk factors of industrial area in southern Poland. Exp Clin Endocrinol Diabetes 2009;117:350-3
   PubMed Web of Science ®Google Scholar
• Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Diabetes Study. Diabetologia 2012;55:88-93.
   PubMed Web of Science ®Google Scholar
• Doneva M, Valov V, Borisova AM, et al. Comparative analysis of the cost of insulin treated patients in Bulgaria. Biotechnol Biotec Eq 2013;27:3748-52
   Web of Science ®Google Scholar
• Croatian Health Insurance Fund. Health services price list and codebook. http://www.hzzo-net.hr/04_01_08.php. Accessed October 2012
   Google Scholar
• Business Report of Croatian Health Insurance Fund for 2011. Zagreb: Croatian Health Insurance Fund, 2012
   Google Scholar
• Státni ústav pro kontrolu léčiv (State Institute for Drug Control). http://www.sukl.eu. Accessed November 2013
   Google Scholar
• “Public Note of the Czech Ministry of Health no.134/1998, Coll.ofActs,” and “Public Note of the Czech Ministry of Health no.396/2010, Coll. Of Acts,” Ministerstvo Zdravotnictví České Republiky (Ministry of Health of the Czech Republic). http://www.mzcr.cz. Accessed November 2013
   Google Scholar
• National Health Found. 2013 Contract Guide. http://www.nfz.gov.pl/new/index.php. Accessed January 2013
   Google Scholar
• Antoñanzas F, Brenes F, Molero JM, et al. Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain. Actas Urol Esp 2011;35:65-71
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
   PubMedGoogle Scholar
• Cots F, Raventòs J, Ausín P, et al. The day hospital: analysis of results, costs and management of pneumology resources. Arch Bronconeumol 2013;49:54-62
   PubMed Web of Science ®Google Scholar
• Oliva J, Lobo F, Begoña M, et al. Estudio de los costes directos sanitarios de los pacientes con diabetes mellitus en España. XXIII Jornadas de la Asociación de Economía de la Salud 2003
   Google Scholar
• OECD. Health expenditure since, 2000. http://stats.oecd.org/. Accessed May 2015
   Google Scholar
• Eurostat. Health care expenditure by function. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_sha_hc&lang=en. Accessed May 2015
   Google Scholar
• Eurostat. Employment rate by gender, age group 20-64. http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init =1&plugin =1&language=en&pcode=t2020_10 (2012). Accessed December 2012
   Google Scholar
• Croatian Bureau of Statistics. http://www.dzs.hr/. Accessed October 2012
   Google Scholar
• Český Statistický Úřad (Czech Statistical Office). http://www.czso.cz. Accessed October 2012
   Google Scholar
• Hungarian Central Statistical Office (HCSO). https://www.ksh.hu/docs/hun/xftp/gyor/let/let21412.pdf. Accessed October 2012
   Google Scholar
• Główny Urząd Statystyczny (Central Statistical Office of Poland). http://stat.gov.pl. Accessed September 2012
   Google Scholar
• Statistični Urad Republike Slovenije (Statistical Office of the Republic of Slovenia). http://www.stat.si. Accessed October 2012
   Google Scholar
• Instituto Nacional de Estadística. http://ine.es. Accessed May 2015
   Google Scholar
• Leśniowska J, Schubert A, Wojna M, et al. Costs of diabetes and its complications in Poland. Eur J Health Econ 2014;15:653-60
   PubMed Web of Science ®Google Scholar
• Vokó Z, Nagyjánosi L, Kaló Z. Direct health care costs of diabetes mellitus in Hungary. LAM 2009;19:775-80
   Google Scholar
• Lopez-Bastida J, Boronat M, Moreno JO, et al. Costs, outcomes and challenges for diabetes care in Spain. Global Health 2013;9:17
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202
   PubMedGoogle Scholar
• Shi L, Shao H, Zhao Y, et al. Is hypoglycemia fear independently associated with health-related quality of life? Health and quality of life outcomes 2014;12:167
   PubMed Web of Science ®Google Scholar
• Williams S, Pollack M, Bolge S, et al. The effects of hypoglycemia on work and life productivity among patients with type 2 diabetes mellitus (T2DM) using oral antidiabetic agents (OADs). American Diabetes Association. 69th Scientific Sessions 2009. Abstract number: 1220-P.
   Google Scholar
• Zhang Y, Wieffer H, Modha R, et al. The burden of hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives. JCOM Journal 2010;12:547-557.
   Google Scholar